Meridian Bioscience (Meridian Bioscience) ROCE % : 4.79% (As of Sep. 2022)

View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Meridian Bioscience's annualized ROCE % for the quarter that ended in Sep. 2022 was 4.79%.

Meridian Bioscience ROCE % Historical Data

The historical data trend for Meridian Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience ROCE % Chart

Meridian Bioscience Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

ROCE %

Get a 7-Day Free Trial

14.05

12.60

18.84

24.45

13.74

Meridian Bioscience Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial															8.16	19.84	35.80	-6.18	4.79

Meridian Bioscience ROCE % Calculation

Meridian Bioscience's annualized ROCE % for the fiscal year that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2022 )		(A: Sep. 2021 )		(A: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2022 )		(A: Sep. 2021 )		(A: Sep. 2022 )
	=	55.506	/	( ( (449.722 - 47.157)	+	(463.097 - 57.951) )	/ 2 )
	=	55.506	/	( (402.565	+	405.146)	/ 2 )
	=	55.506	/	403.8555
	=	13.74 %

Meridian Bioscience's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	19.412	/	( ( (465.928 - 60.347)	+	(463.097 - 57.951) )	/ 2 )
	=	19.412	/	( ( 405.581	+	405.146 )	/ 2 )
	=	19.412	/	405.3635
	=	4.79 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

Meridian Bioscience (NAS:VIVO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Meridian Bioscience ROCE % Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Meridian Bioscience (Meridian Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3471 River Hills Drive, Cincinnati, OH, USA, 45244

Website

https://www.meridianbioscience.com

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Executives

Julie Diana Smith	officer: Sr VP, Controller, PAO	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny	director, officer: Chief Executive Officer	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller	officer: EVP & CFO	ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare	officer: Interim CFO & Chief Acctg Off	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii	director	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna	officer: Executive VP-Diagnostics	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams	director	C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini	officer: Exec VP, Operations & IS	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen	officer: EVP, Bus. Development/Strategy	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien	officer: EVP, Life Science	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244